Introduction: Diabetes and atherosclerosis are both risk factors of cognitive deficits. Scavenger receptor CD36 is associated with increasing risk of diabetes and atherosclerosis, and may play a role in cognitive deficits. The aim of this study is to determine the correlations of plasma soluble CD36 concentrations with carotid intima-media thickness (IMT) and cognitive function in patients with type 2 diabetes. Material and methods: We determined the levels of soluble CD36 (sCD36), blood lipids, fasting blood glucose, glycosylated hemoglobin, carotid atherosclerosis as IMT, cognitive function by the Montreal Cognitive Assessment (MoCA) scoring system, and other clinical characteristics in 357 patients with type 2 diabetes. Results: Diabetic patients with the lowest quartile of IMT (Q1) had lower sCD36 concentrations (ANOVA, p trend < 0.05) and higher MoCA scores than upper ones (Q2-Q4) (p trend < 0.05), and those with the highest quartile of sCD36(Q4) had higher FBG, LDL-C and carotid IMT than lower ones (Q1-Q3) (p trend < 0.05 for all). Plasma log 10 (sCD36) was significantly correlated with carotid IMT (r = 0.202, p < 0.001) after adjustment for age, gender, and education level. Carotid IMT was significantly associated with MoCA scores (r = 0.284, p < 0.001) after adjustment for, age, gender, education level, duration of DM and hypertension. There were no correlations between sCD36 and MoCA scores (r = -0.038, p = 0.470). Conclusions: Our study shows that sCD36 is associated with carotid IMT, and carotid IMT is inversely correlated with cognitive function in type 2 diabetic patients. Nevertheless, no cross-sectional association between sCD36 and MoCA scores was detected in this study.
Introduction
Diabetes is becoming a major health problem all over the world. Cardiovascular disease (CVD) risk is 2-to 8-fold higher in the diabetic population than it is in non-diabetic individuals of a similar age, sex and ethnicity [1, 2] . Additionally, there is growing evidence that chronic hyperglycemia has various negative effects on the central and peripheral nervous system [3, 4] . Several studies have indicated that diabetes can be a risk factor for the development of mild cognitive impairment (MCI) and dementia [5] [6] [7] . Epidemiological and basic science evidence suggest a possible shared pathophysiology between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) [8] . A diagnosis of diabetes increased the odds of cognitive decline 1.2-to 1.7-fold, and the odds of future dementia 1.6-fold [9] . Thus, cognitive dysfunction has been suggested to be one of the chronic complications of diabetes by many investigators.
Besides diabetes, atherosclerosis is also a risk factor of cognitive deficits. Links between atherosclerosis and cognitive impairment in people with [10] and without diabetes [11] are increasingly recognized. Many vascular risk factors, including increasing carotid intima-media thickness (carotid IMT) [12] , low ankle brachial index (ABI) [13] , hypercholesterolemia [14] and hypertension [15] , have been implicated in the development of cognitive decline and dementia.
Scavenger receptor CD36 is a transmembrane glycoprotein expressed in a variety of tissues which has been shown to be involved in angiogenesis, inflammation, lipid metabolism, and atherosclerosis [16] [17] [18] . Recently, Park et al. [19] suggested that CD36 may promote vascular amyloid deposition and cerebrovascular damage, leading to neurovascular dysfunction and cognitive impairment. Soluble CD36 (sCD36) in plasma was proposed to reflect tissue CD36 expression and may thus be a potential marker associated with atherosclerosis [20] . A growing body of evidence suggests that elevated sCD36 is associated with carotid atherosclerosis [21] , insulin resistance and higher type 2 diabetes risk [22] .
Although CD36 may play a role in cognitive impairment, and sCD36 was considered to be correlated with carotid atherosclerosis, little is known about the correlations among plasma soluble CD36 concentrations, carotid IMT and cognitive function in patients with type 2 diabetes. In the present study we aimed to determine the individual and combined associations of sCD36 and carotid and cognitive function of patients with type 2 diabetes in Shanghai, China. The exclusion criteria were as follows: (1) diabetic ketoacidosis or other acute diabetic complications in the last 3 months, severe heart failure, chronic renal failure, lung disease, or a history of infection in the central nervous system, stroke, cerebral hemorrhage or other clinical evidence of central nervous damage; (2) history of auditory disorders and psychological disturbances, which might interfere with the MoCA test; (3) history of chronic disease which could cause dementia (including Alzheimer syndrome, Parkinson syndrome, vascular dementia, Huntington's disease, hydrocephalus, brain neoplasm, epilepsy, multiple sclerosis, chronic subdural hematoma, severe head trauma, abnormal brain structure, schizophrenia, etc.); (4) history of alcohol abuse or drug abuse; (5) history of depression and taking antidepressants within 6 months before recruitment; (6) use of possible or known drugs associated with cognitive impairment in the previous month (e.g.: steroids, antiepileptic drug, sedative-hypnotic drugs, anesthetics, etc.).
Material and methods

Patients
The study was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association and approved by the local medical ethics committee. Written informed consent was obtained from all participants.
Anthropometric measurements
All the subjects underwent an interview including age, sex, education level, history of smoking, history of drinking, history of hypertension and duration of DM. Data of waist circumference, body mass index (BMI), and blood pressure were collected. Hypertension was defined as systolic (SBP) or diastolic blood pressure (DBP) ≥ 140 mm Hg, or 90 mm Hg, respectively, or self-reported current use of blood pressure lowering medication. Medication and supplement use data were obtained for use of lipid-lowering medications, antidiabetes medications, antihypertensive medications, and antiplatelet medications through questionnaires and pill bottle reviews.
Laboratory measurements
Levels of sCD36 were measured by use of the commercially available enzyme-linked immunosorbent assay (ELISA) kits (BlueGene, Shanghai, China). The inter and intra-assay coefficient of variation (CV) was 15% and 8%. Fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured enzymatically on an automatic analyzer (Cobas 8000 C701 C502 auto chemistry analyzer, Roche, USA). Glycosylated hemoglobin (HbA 1c ) was quantified from resolved erythrocytes with high performance liquid chromatography (HLC-723G7 analyzer, TOSOH kabushiki kaisha, Japan).
Ultrasonography of carotid arteries
Color Doppler ultrasound (Sequoia scanner, SIEMENS, Germany) was used to image the right and left common carotid arteries (CCA). By using an automated edge detection system, IMT was measured between the lumen intima and media-adventitia interfaces of the far wall of the CCA (the 1 cm segment proximal to the bifurcation). The mean IMT of this 1 cm segment was measured and the mean of measurements on both sides was used as the carotid IMT.
Statistical analysis
All continuous data were tested for normality using the Kolmogorov-Smirnov (KS) test. Because of skewness and kurtosis of the distributions, serum triglyceride and plasma sCD36 concentrations were logarithmically transformed for statistical analyses and then back-transformed to their natural units for presentation in text and tables. One-way ANOVA and Tukey's post hoc analysis were used to analyze the difference of clinical characteristics by quartiles (Q1-Q4) of carotid IMT and sCD36. The c 2 test was used for comparison of categorical variables. Univariate analysis was performed using Pearson correlation analysis or Spearman rank correlation. The factors influencing sCD36, carotid IMT and MoCA score were analyzed using partial correlation analyses. These analyses were performed using the Statistical Package for the Social Sciences (SPSS Version 19.0, IBM). Results are expressed as mean ± SD or median (25-75%). A p-value of less than 0.05 was considered to be significant.
Results
The demographic, anthropometric, and clinical characteristics of the study population are presented in Table I Table II presents the demographic, anthropometric, and clinical predictors of carotid IMT. Patients with the highest IMT were older, had less education, longer duration of diabetes, had higher proportion of hypertension, waist circumference, SBP, DBP, TC, TG, HDL-C, LDL-C, sCD36, and lower MoCA scores (ANOVA, p trend < 0.05) ( Figure 1 ). Table III presents the demographic, anthropometric, and clinical predictors of plasma sCD36. Patients with the highest sCD36 had higher FBG, LDL-C and carotid IMT (ANOVA, p trend < 0.05) (Figure 2) .
Univariate analysis revealed significant correlations between plasma sCD36 and age, sex, edu- (Table IV) . No correlation between sCD36 and MoCA scores was observed in this study (r = -0.038, p = 0.470) (Figure 3 C) .
Discussion
In this cross-sectional study, we found that soluble CD36 concentrations were associated with carotid IMT, which has a strong association with subclinical and/or silent atherosclerosis [23] , and also is a strong predictor of CVD [24] . Furthermore, IMT was inversely correlated with cognitive function in diabetic patients, which was in accordance with the results of previous research [25, 26] . However, we did not find any relationship between sCD36 and MoCA scores, indicating that concentrations of soluble sCD36 may have no correlation with cognitive function of patients with type 2 diabetes.
Previous studies have demonstrated an association between high CD36 expression and atherosclerosis risk [27] , and it may become a useful tool in cardiovascular disease risk stratification [28] . Handberg et al. [20] identified the existence and availability of soluble CD36 in plasma for further research discovery in 2008. Recently, they suggested that both too much and too little sCD36 may be associated with an increased atherosclerosis risk in clinically healthy people [29] . Previous studies have indicated that carotid IMT is a risk marker of micro-and macrovascular complications in diabetic patients [30, 31] . Our findings of significant correlations between sCD36 and carotid IMT in type 2 diabetic patients are partly in agreement with the results of Handberg et al. [29] in a nondiabetic population. However, unlike the J-shape relationship between sCD36 and carotid IMT in the research of Handberg et al., the results of our study show lower levels of sCD36 in the lowest quartile of IMT (Q1) than upper ones (Q2-Q4) (Figure 1 A) , and higher IMT in the highest quartile of sCD36 (Q4) than lower ones (Q1-Q3) (Figure 2 C) . These findings suggest that plasma sCD36 may be elevated at the early stage of atherosclerosis, but may not sensitively predict the progression of increased IMT in the diabetic population. Biological markers are becoming important in early diagnosis of cognitive impairment. Brain-derived neurotrophic factor (BDNF) has been shown to protect neurons from damage caused by infection or injury [32] . A study of Zhen et al. indicated that decreased BDNF [33] could be associated with cognitive deficits in patients with type 2 diabetes. Qin et al. determined that the absence of CD36 could rescue the angiogenesis deficit in mice with the BDNF SNP [34] . Park et al. [19] found that Tg2576 mice lacking CD36 have a selective reduction in amyloid-β 40 (Aβ1-40) and cerebral amyloid angiopathy (CAA), which contribute to the occurrence of AD, indicating that CD36 may lead to cognitive deficits in rodents. Another study [35] reported that compared with wild-type brains, CD36 knock-out mouse brains showed less accu-mulation of microglia, which is associated with Aβ deposition. Additionally, the study of Stewart et al. [36] showed that amyloid-beta triggers inflammatory signaling through a heterodimer of toll-like receptors 4 and 6 regulated by signals from CD36. These results suggest that CD36 may play a key role in the proinflammatory events associated with AD and cognitive impairment. However, it remains unknown whether increased expression of CD36 and its plasma marker sCD36 can be a risk marker of cognitive deficits in patients with diabetes. On the other hand, Giunta et al. [37] reported decreased leukocyte expression of CD36 in patients with Alzheimer's disease and mild cognitive impairment. Also, Wang et al. [38] found that AD-like pathogenesis increased oxidative stress, exacerbated inflammation, and was associated with a marked reduction in CD36 expression, and intranasal therapy with a lentiviral vector encoding human nuclear factor erythroid-2-related factor 2 (Nrf2) can diminish Aβ deposition and improve spatial memory defects by directly increasing CD36 expression. Additionally, Yamanaka et al. [39] reported that activation of PPARγ, which is mediated by upregulation of CD36 expression, may result in improved microglial Aβ phagocytosis. It seems that CD36 may have a dual-directional regulation effect on the central nervous system. The expression of CD36 may not reflect the cognitive function or predict risks of cognitive impairment in diabetic patients. Future longitudinal studies investigating the interrelationship among CD36, atherosclerosis and cognitive impairment in type 2 diabetes are warranted.
Our study is limited by its cross-sectional design, and residual confounding and reverse causation are potential concerns, as in any cross-sectional study. Moreover, all the findings corresponding to carotid IMT are not necessarily coronary atherosclerosis as well as cardiovascular events. Cohort studies are necessary to determine the association of sCD36 concentrations and future cardiovascular events in patients with type 2 diabetes. The sample size in our study was relatively small, so it remains a possibility that there is a real association between sCD36 and cognitive function among diabetic patients and that our study was underpowered to detect it. Additionally, a preselected highrisk population was chosen in this study, which may considerably bias the sensitivity and specificity of the tests.
In conclusion, our study shows that a higher level of plasma sCD36 is associated with carotid IMT in patients with type 2 diabetes, independent of age, gender, education level and duration of diabetes. Also, carotid IMT is inversely correlated with cognitive function in the same subjects. However, we failed to detect a significant association between sCD36 and MoCA scores, suggesting that elevated sCD36 cannot be a risk marker of cognitive deficits in type 2 diabetic patients.
